Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era
Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era
复制标题
利妥昔单抗时代滤泡性淋巴瘤与弥漫性大B细胞淋巴瘤成分共存患者的临床特征及预后
DOI：
10.1007/s00432-022-04381-8
复制
发表时间：
2022-10
影响因子：
3.6
通讯作者：
胡建达
中科院分区：
文献类型：
--
作者：
陈溢;罗璐婷;陈鹭珊;郑晓云;杨小珠;郑志宏;郑静;刘庭波;杨婷;胡建达
目的本研究旨在探讨FL/DLBCL共存患者的临床病理特征及预后。方法回顾性分析2013年1月至2021年12月诊断为FL/DLBCL （n= 56）、纯FL （n= 260）或新生DLBCL (n= 812)（对照）患者的临床特征和预后。结果FL/DLBCL患者的中位年龄为52岁。DLBCL成分的含量在5% ~ 95%之间。56例FL/DLBCL中，生发中心b细胞（GCB）来源占67.9%，非GCB来源占26.8%，未分类占5.3%。FL/DLBCL患者的临床特征为中间型，介于FL和DLBCL之间。对基线特征相似且接受利妥昔单抗联合环磷酰胺、阿霉素或表阿霉素、vindesine和强的松（R-CHOP）方案的患者进行倾向评分匹配。与FL患者相比，FL/DLBCL患者的预后较差，完全缓解（CR）率、无进展生存期（PFS）和总生存期（OS）较低。骨髓受累和B症状被确定为FL/DLBCL患者PFS的独立不良预后因素。当接受R-CHOP方案时，FL/DLBCL患者的CR率和PFS较低，但OS与DLBCL患者相似。结论在利妥昔单抗时代，FL/DLBCL患者的治疗反应和生存期低于单纯FL患者，CR率和PFS较低，但OS与DLBCL患者相似。
PurposeThis single-centre study aimed to determine the clinicopathological characteristics and prognosis for patients with co-existing FL and DLBCL components (FL/DLBCL).MethodsWe retrospectively analysed the clinical characteristics and prognosis of patients diagnosed with FL/DLBCL (n= 56) and with pure FL (n= 260) or de novo DLBCL (n= 812) (controls) between January 2013 and December 2021.ResultsThe median age of patients with FL/DLBCL was 52 years. The amount of the DLBCL component ranged from 5 to 95%. Among the 56 FL/DLBCL cases analysed, 67.9% were of germinal centre B-cell (GCB) origin, 26.8% non-GCB origin, and 5.3% were unclassified. The clinical features of patients with FL/DLBCL were intermediate, falling between those of FL and DLBCL. Propensity-score matching was performed for patients with similar baseline characteristics who were receiving the rituximab plus cyclophosphamide, doxorubicin or epirubicin, vindesine, and prednisone (R-CHOP) regimen. Patients with FL/DLBCL showed inferior outcomes compared to those with FL, with a lower complete remission (CR) rate, progression-free survival (PFS), and overall survival (OS). Bone marrow involvement and B symptoms were identified as independent adverse prognostic factors for PFS among patients with FL/DLBCL. Patients with FL/DLBCL presented a lower CR rate and PFS but similar OS to those with DLBCL when receiving the R-CHOP regimen.ConclusionPatients with FL/DLBCL showed inferior treatment response and survival than those with pure FL and had a lower CR rate and PFS, but similar OS to those with DLBCL in the rituximab era.
登录
查看更多内容
影响因子：
20.3
作者：
Hans, CP;Weisenburger, DD;Armitage, JO
通讯作者：
Armitage, JO
影响因子：
50.5
作者：
Dreyling, M.
通讯作者：
Dreyling, M.
影响因子：
50.5
作者：
Dreyling, M.;Ghielmini, M.;Ladetto, M.
通讯作者：
Ladetto, M.
影响因子：
4.8
作者：
Pham, R. N.;Gooley, T. A.;Gopal, A. K.
通讯作者：
Gopal, A. K.
DOI：
10.1016/j.hoc.2020.03.001
发表时间：
2020-08
期刊：
Hematology/oncology clinics of North America
影响因子：
--
作者：
C. Casulo
通讯作者：
C. Casulo